STOCK TITAN
  1. Home
  2. Sec-filings
  3. RSLS
  4. [Form 4] Vyome Holdings, Inc Insider Trading Activity

RSLS Form 4: CEO Converted 35,000 Legacy Shares into 7 New Shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vyome Holdings Form 4: This Form 4 reports that Venkat Nelabhotla, President, CEO and a director, received 7 shares of Vyome Holdings common stock as a result of a merger on 08/15/2025. Under the Merger Agreement, each 5,000 shares of Vyome Therapeutics common stock converted into 1 share of Vyome Holdings common stock. The reporting person exchanged 35,000 Vyome Therapeutics shares and received 7 Vyome Holdings shares. The Form 4 was filed as a single reporting person and is signed on 09/22/2025.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Insider received a nominal number of parent shares from a merger conversion, immaterial to valuation.

The transaction reflects the mechanical equity conversion in the Merger Agreement: a 1-for-5,000 conversion ratio produced 7 shares from 35,000 legacy shares. There is no cash consideration disclosed and no additional purchases or sales reported by the insider. Given the very small resulting share quantity reported for the insider, this specific filing is unlikely to materially affect outstanding share count or investor valuation.

TL;DR: Transaction documents a routine post-merger exchange by an executive; governance disclosure appears complete.

The Form 4 discloses the reporting person’s dual role as President/CEO and director and transparently records the conversion of Vyome Therapeutics equity into Vyome Holdings common stock under the Merger Agreement. The filing includes transaction and signature dates and indicates it was filed by one reporting person, satisfying Section 16 reporting mechanics. No indications of unusual timing or related-party sales are disclosed in this form.

Insider Nelabhotla Venkateswarlu
Role President and CEO
Type Security Shares Price Value
Grant/Award Common Stock 7 $0.00 $0.00
Holdings After Transaction: Common Stock — 7 shares (Direct)
Footnotes (1)
  1. F1. Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 7 shares of the Issuer's common stock in exchange for 35,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.

FAQ

What did Venkat Nelabhotla report on the Form 4 for RSLS?
The Form 4 reports that Venkat Nelabhotla received 7 shares of Vyome Holdings common stock following a merger conversion on 08/15/2025.

What was the conversion ratio used in the merger disclosed on the Form 4?
The Merger Agreement converted Vyome Therapeutics shares into Vyome Holdings common stock at a ratio of 1 share per 5,000 shares of Vyome Therapeutics.

How many Vyome Therapeutics shares were exchanged to receive the 7 Vyome Holdings shares?
The reporting person exchanged 35,000 shares of Vyome Therapeutics common stock and received 7 shares of Vyome Holdings common stock.

When was the Form 4 signed and filed?
The Form 4 shows a signature date of 09/22/2025 and records the transaction date as 08/15/2025.

What roles does the reporting person hold at Vyome Holdings as disclosed?
The reporting person is disclosed as a Director and as an Officer with the title President and CEO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Nelabhotla Venkateswarlu
(Last) (First) (Middle)
C/O VYOME HOLDINGS, INC.
HARVARD SQUARE, ONE MIFFLIN PLC, ST. 400
(Street)
CAMBRIDGE MA 02138
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Vyome Holdings, Inc [ HIND ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/15/2025 A(1) 7 A (1) 7 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 7 shares of the Issuer's common stock in exchange for 35,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.
/s/ Venkat Nelabhotla 09/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR